Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels
Anna Wonnerth1, Katharina M Katsaros2, Konstantin A Krychtiuk1
1Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Metabolism: Clinical and Experimental
|March 18, 2014
Summary
Genetic variations in glycoprotein 130 (gp130) influence soluble gp130 (sgp130) levels. Individuals with the gp130 G148C polymorphism exhibit higher sgp130 serum concentrations, potentially impacting inflammatory disease responses.
Area of Science:
- Immunology
- Genetics
- Cardiovascular Disease Research
Background:
- Interleukin-6 (IL-6) is a critical cytokine in inflammatory processes.
- Soluble glycoprotein 130 (sgp130) acts as a natural inhibitor of IL-6 trans-signaling.
- Understanding factors influencing sgp130 levels is crucial for managing inflammatory diseases.
Purpose of the Study:
- To investigate the potential impact of the glycoprotein 130 (gp130) genotype on serum levels of soluble gp130 (sgp130).
- To determine if the G148C polymorphism in gp130 is associated with variations in sgp130 serum concentrations.
Main Methods:
- Genotyping for the gp130 G148C polymorphism was performed in two distinct male populations (OSLO and VIENNA).
- Serum levels of sgp130, IL-6, and soluble IL-6 receptor (sIL-6R) were quantified.
- Statistical analyses, including multivariate linear regression, were employed to assess associations.
Main Results:
- Subjects with the gp130 G148C polymorphism demonstrated significantly higher sgp130 serum levels in both populations.
- This association remained statistically significant after adjusting for other factors.
- Elevated sgp130 levels were also observed in diabetic patients (VIENNA), and in individuals with higher BMI and smoking status (OSLO).
Conclusions:
- Serum sgp130 levels are significantly influenced by the presence of the gp130 G148C polymorphism.
- This genetic variation may play a role in modulating an individual's response to inflammatory conditions.
- The findings suggest a genetic component affecting sgp130 levels and their role in inflammatory diseases.
More Related Videos
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:05Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
02:50Conjugated Proteins
21.1K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
21.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:25Protein Glycosylation
8.4K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
8.4K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81